Literature DB >> 29863273

Metabolomic changes in human adipose tissue derived products following non-enzymatic microfacturing.

M Garcia-Contreras1, F Messaggio, A J Mendez, C Ricordi.   

Abstract

OBJECTIVE: In this study, we evaluated the metabolomic profiling of cryopreserved Lipogems® tissue products and the initial lipoaspirates before microfracturing, to determine altered metabolites that could result from the non-enzymatic processing or the cryopreservation method.
MATERIALS AND METHODS: Human Lipoaspirate samples (n=10) were divided in two aliquots, of which one was non-processed and the other was processed by Lipogems® device. Non-processed lipoaspirates and Lipogems® processed tissues were stored at -80°C fresh frozen (N=3 per group) or in the presence of 0.5 M dimethyl sulfoxide (DMSO) (N=7 per group). A global non-targeted metabolic profile on these samples was performed.
RESULTS: Differences were observed in carbohydrate and nucleotide metabolism. These alterations translated in long chain and polyunsaturated fatty acid levels and amino acid metabolites showed divergent trends. When Lipogems® and Lipoaspirate tissue products were cryopreserved with DMSO, amino acids tended to increase in Lipogems® product. However, in the absence of DMSO aminoacids and their catabolites, tended to decrease in Lipogems® fat tissue product.
CONCLUSIONS: Microfractured human adipose tissue has been shown to provide a more effective source of adult stromal cells compared to the initial lipoaspirated tissue material. These could be, according to our findings, due to the changes in the metabolic profile of lipoaspirate tissues products.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29863273     DOI: 10.26355/eurrev_201805_15088

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  1 in total

1.  Autologous micro-fragmented adipose tissue for the treatment of diabetic foot minor amputations: a randomized controlled single-center clinical trial (MiFrAADiF).

Authors:  Roberto Lonardi; Nicola Leone; Stefano Gennai; Giulia Trevisi Borsari; Tea Covic; Roberto Silingardi
Journal:  Stem Cell Res Ther       Date:  2019-07-29       Impact factor: 6.832

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.